Severe Esophageal Ulceration With Enfortumab Vedotin Plus Pembrolizumab Therapy in Urothelial Carcinoma: A Case Report

Clinicians must be vigilant for severe esophageal toxicity during EV+P therapy. While pembrolizumab-induced irAE is the primary suspect, EV-associated mucocutaneous toxicity remains a potential differential diagnosis. Early recognition and prompt high-dose corticosteroid therapy can lead to successful management without permanent sequelae.